Factors for Impairment of Renal Graft Function in Intensive Care
Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Dec 20, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how being in the intensive care unit (ICU) may affect kidney transplant success over time. Researchers want to understand the factors that can lead to problems with kidney function in patients who have received a kidney transplant and have been hospitalized in the ICU. The goal is to identify risks that could harm the kidney graft for up to two years after the hospital stay. This information can help doctors better manage kidney care during and after ICU treatment.
To participate in this study, you need to be over 18 years old and have received a kidney transplant. The trial is looking for patients who are being admitted to the ICU for the first time. However, if you were already on kidney dialysis before going to the ICU or were transferred to the ICU immediately after your transplant, you would not be eligible. If you join the study, you can expect regular follow-ups to monitor your kidney health and help improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • kidney graft
- • \> 18 years
- • first hospitalization in ICU
- Exclusion Criteria:
- • chronic hemodialysis before ICU
- • transfer to intensive care immediately after transplant within 24 hours
About Central Hospital, Nancy, France
Central Hospital, located in Nancy, France, is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies across various therapeutic areas, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Central Hospital leverages its state-of-the-art facilities and expertise to contribute to the development of cutting-edge treatments and enhance the overall quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nancy, , France
Patients applied
Trial Officials
Sébastien GIBOT
Principal Investigator
CHU NANCY Central
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported